A study to examine the tolerability and antiviral activity of switching to Biktarvy tablets taken once daily compared to baseline over 48 weeks in HIV-1 infected antiretroviral therapy (ART) experienced participants aged 55 years and older who are virologically suppressed on a current antiretroviral regimen (CAR).
Not Applicable
Not yet recruiting
- Conditions
- Human Immunodeficiency Virus
- Registration Number
- ACTRN12618001340224
- Lead Sponsor
- Taylor Square Private Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method